Scalp Psoriasis: Systematic Review Comparing Topical Treatments and Placebo
Regina Jales1, Sérgio Hirata2, Álvaro Attalah3, Danúbia Sá-Caputo4, Adriano Arnóbio5, Éric Heleno Frederico5, Mario Bernardo-Filho5, Humberto Saconato1
1Departamento de Clínica Médica, Hospital Universitário Onofre Lopes, Universidade Federal do Rio Grande do Norte, Natal, Brazil.
2Departamento de Dermatologia, Hospital Sao Paulo, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
3Departamento de Medicina Interna, Hospital Sao Paulo, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
4Programa de Pós-Graduacao em Fisiopatologia Clínica e Experimental, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
5Departamento de Biofísica e Biometria, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
DOI: 10.4236/jcdsa.2015.52017   PDF   HTML   XML   3,959 Downloads   5,179 Views  


Patients with scalp psoriasis suffered from a lower quality of life relating to the highly visible site of their psoriatic lesions. In consequence this fact stimulates investigations involving treatments of this dermatologic disease. The aim of this review is to evaluate the topical treatments for scalp psoriasis compared with placebos. Methods: A systematic review was performed using searches in the database LILACS, MEDLINE, Cochrane Library, and Embase. As selection criteria were chosen eligible publications involving randomized controlled trials, patients with scalp psoriasis diagnosed clinically or by biopsy, interventions with topical treatments for scalp psoriasis compared with placebo. Outcome related to the reduction in severity of psoriasis of the scalp, assessed by physicians and patients, and assessment of adverse effects that required discontinuation of treatment. The results have shown that the patients were aged 12 to 97 years, including 3441 patients. Ten of the fifteen studies included reported gender data. Patients were mostly female. Twelve studies were about psoriasis’s severity. These studies in which the severity has been described, the classification of severity was mild (0 study), mild to moderate (1 study), moderate to severe (11 studies) and severe (0 study). In conclusion, topical corticosteroids, calcipotriol, ciclopirox olamine and associations between them are effective in the treatment of scalp psoriasis. Clobetasol propionate (0.05%) was the most effective active ingredient in several vehicles in the induction treatment of scalp psoriasis.

Share and Cite:

Jales, R. , Hirata, S. , Attalah, Á. , Sá-Caputo, D. , Arnóbio, A. , Frederico, É. , Bernardo-Filho, M. and Saconato, H. (2015) Scalp Psoriasis: Systematic Review Comparing Topical Treatments and Placebo. Journal of Cosmetics, Dermatological Sciences and Applications, 5, 142-150. doi: 10.4236/jcdsa.2015.52017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Huerta, C., Rivero, E. and Rodriguez, L.A. (2007) Incidence and Risk Factors for Psoriasis in the General Population. Archives of Dermatology, 143, 1559-1565.
[2] Braathen, L.R., Botten, G. and Bjerkedal, T. (1989) Prevalence of Psoriasis in Norway. Acta Dermato-Venereologica, 142, 5-8.
[3] Nevitt, G.J. and Hutchinson, P.E. (1966) Psoriasis in the Community: Prevalence, Severity and Patients’ Beliefs and Attitudes towards the Disease. British Journal of Dermatology, 135, 533-537.
[4] Lomholt, G. (1963) Psoriasis: Prevalence, Spontaneous Course and Genetics. A Census Study on the Prevalence of Skin Disease on the Faroe Islands. G.E.C. Gad, Copenhagen.
[5] Zeljko-Penavic, J., Situm, M., Simic, D. and Vurnek-Zivkovic, M. (2010) Quality of Life in Psoriatic Patients and the Relationship between Type I and Type II Psoriasis. Collegium Antropologicum, 34, 195-198.
[6] Kastelan, M., Prpic-Massari, L. and Brajac, I. (2009) Apoptosis in Psoriasis. Acta Dermatovenerologica Croatica, 17, 182-186.
[7] Castelijns, F.A., Gerritsen, M.J., van Erp, P.E. and van de Kerkhof, P.C. (2000) Cell-Kinetic Evidence for Increased Recruitment of Cycling Epidermal Cells in Psoriasis: The Ratio of Histone and Ki-67 Antigen Expression Is Constant. Dermatology, 201, 105-110.
[8] Soler, D.C. and McCormick, T.S. (2011) The Dark Side of Regulatory T Cells in Psoriasis. Journal of Investigative Dermatolology, 131, 1785-1786.
[9] Chan, C.S., Van Voorhees, A.S., Lebwohl, M.G., Korman, N.J., Young, M., Bebo, B.F., et al. (2009) Treatment of Severe Scalp Psoriasis: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 60, 962-971.
[10] Tracey, W. (2010) Psoriasis: Impact and Management of Moderate to Severe Disease. British Journal of Nursing, 19, 10-17.
[11] Rongioletti, F., Fiorucci, C. and Parodi, A. (2009) Psoriasis Induced or Aggravated by Drugs. Journal of Rheumatology, 83, 59-61.
[12] Telfer, N.R., Chalmers, R.J., Whale, K. and Colman, G. (1992) The Role of Streptococcal Infection in the Initiation of Guttate Psoriasis. Archives of Dermatolology, 128, 39-42.
[13] Navarini, A.A. and Trueb, R.M. (2010) Psoriasis. Therapeutische Umschau, 67, 153-165.
[14] Van de Kerkhof, P.C., de Hoop, D., de Korte, J. and Kuipers, M.V. (1998) Scalp Psoriasis Clinical Presentations and Therapeutic Management. Dermatology, 197, 326-334.
[15] Farber, E.M. and Nall, M.L. (1974) The Natural History of Psoriasis in 5,600 Patients. Dermatologica, 148, 1-18.
[16] Ortonne, J., Chimenti, S., Luger, T., Puig, L., Reid, F. and Trüeb, R. (2009) Scalp Psoriasis: European Consensus on Grading and Treatment Algorithm. Journal of the European Academy of Dermatology & Venereology, 23, 1435-1444.
[17] Kim, G.W., Jung, H.J., Ko, H.C., Kim, M.B., Lee, W.J., Lee, S.J., Kim, D.W., et al. (2011) Dermoscopy Can Be Useful in Differentiating Scalp Psoriasis from Seborrhoeic Dermatitis. British Journal of Dermatology, 164, 652-656.
[18] Mashaly, H.M., Masood, N.A. and Mohamed, A.S. (2011) Classification of Papulo-Squamous Skin Diseases Using Image Analysis. Skin Research and Technology, 18, 36-44.
[19] Del Rosso, J.Q. (2011) Adult Seborrheic Dermatitis: A Status Report on Practical Topical Management. The Journal of Clinical Aesthetic Dermatology, 4, 32-38.
[20] Kimball, A.B., Guerin, A., Tsaneva, M., Yu, A.P., Wu, E.Q., Gupta, S.R., et al. (2011) Economic Burden of Comorbidities in Patients with Psoriasis Is Substantial. Journal of the European Academy of Dermatology & Venereology, 25, 157-163.
[21] Antoni, C.E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G.R., Schneider, U., et al. (2005) Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis & Rheumatism, 52, 1227-1236.
[22] Mazzotta, A., Esposito, M., Carboni, I., Schipani, C. and Chimenti, S. (2007) Clobetasol Propionate Foam 0.05% as a Novel Topical Formulation for Plaque-Type and Scalp Psoriasis. Journal of Dermatological Treatment, 8, 84-87.
[23] Spandonaro, F., Altomare, G., Berardesca, E., Calzavara-Pinton, P., Chimenti, S., Girolomoni, G., et al. (2011) Health-Related Quality of Life in Psoriasis: An Analysis of Psocare Project Patients. Giornale Italiano di Dermatologia e Venereologia, 146, 169-178.
[24] Basra, M.K., Fenech, R., Gatt, R.M., Salek, M.S. and Finlay, A.Y. (2008) The Dermatology Life Quality Index 1994-2007: A Comprehensive Review of Validation Data and Clinical Results. British Journal of Dermatology, 159, 997-1035.
[25] Shikiar, R., Bresnahan, B.W., Stone, S.P., Thompson, C., Koo, J. and Revicki, D.A. (2003) Validity and Reliability of Patient Reported Outcomes Used in Psoriasis: Results from Two Randomized Clinical Trials. Health & Quality of Life Outcomes, 1, 53.
[26] Menter, A., Gordon, K., Carey, W., Hamilton, T., Glazer, S., Caro, I., et al. (2005) Efficacy and Safety Observed during 24 Weeks of Efalizumab Therapy in Patients with Moderate to Severe Plaque Psoriasis. Archives of Dermatolology, 141, 31-38.
[27] Gottlieb, A.B., Chaudhari, U., Baker, D.G., Perate, M. and Dooley, L.T. (2003) The National Psoriasis Foundation Psoriasis Score (NPF-PS) System versus the Psoriasis Area Severity Index (PASI) and Physician’s Global Assessment (PGA): A Comparison. Journal of Drugs in Dermatology, 2, 260-266.
[28] Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al. (2009) The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Medicine, 6, e1000100.
[29] Sofen, H., Hudson, C.P., Cook-Bolden, F.E., Preston, N., Colón, L.E., Colón, L.E, et al. (2011) Clobetasol Propionate 0.05% Spray for the Management of Moderate-to-Severe Plaque Psoriasis of the Scalp: Results from a Randomized Controlled Trial. Journal of Drugs in Dermatology, 10, 885-892.
[30] Olsen, E.A., Cram, D.L., Ellis, C.N., Hickman, J.G., Jacobson, C., Jenkins, E.E., et al. (1991) A Double-Blind, Vehicle-Controlled Study of Clobetasol Propionate 0.05% (Temovate) Scalp Application in the Treatment of Moderate to Severe Scalp Psoriasis. Journal of the American Academy of Dermatology, 24, 443-447.
[31] Jarratt, M., Breneman, D., Gottlieb, A.B., Poulin, Y., Liu, Y. and Foley, V. (2004) Clobetasol Propionate Shampoo 0.05%: A New Option to Treat Patients with Moderate to Severe Scalp Psoriasis. Journal of Drugs in Dermatology, 3, 367-373.
[32] Franz, T.J., Parsell, D.A., Myers, J.A. and Hannigan, J.F. (2000) Clobetasol Propionate Foam 0.05%: A Novel Vehicle with Enhanced Delivery. International Journal of Dermatology, 39, 535-538.
[33] Reygagne, P., Diaconu, J., Pres, H., Ernst, T.M., Meyer, K.G. and Arsonnaud, S. (2002) Efficacy and Safety Comparison of Clobetasol Propionate Shampoo, Gel and Vehicle in Scalp Psoriasis. European Academy of Dermatology and Venereology, 16, 283.
[34] Franz, T.J., Parsell, D.A., Halualani, R.M., Hannigan, J.F., Kalbach, J.P. and Harkonen, W.S. (1999) Betamethasone Valerate Foam 0.12%: A Novel Vehicle with Enhanced Delivery and Efficacy. International Journal of Dermatolology, 38, 628-632.
[35] Medansky, R.S. and Handler, R.M. (1974) Treating Psoriasis of the Scalp with a New Corticosteroid Lotion. IMJ Illinois Medical Journal, 145, 503-504.
[36] Tyring, S., Mendoza, N., Appell, M., Bibby, A., Foster, R., Hamilton, T., et al. (2010) A Calcipotriene/Betamethasone Dipropionate Two-Compound Scalp Formulation in the Treatment of Scalp Psoriasis in Hispanic/Latino and Black/ African American Patients: Results of the Randomized, 8-Week, Double-Blind Phase of a Clinical Trial. International Journal of Dermatology, 49, 1328-1333.
[37] Harris, J.J. (1972) A National Double-Blind Clinical Trial of a New Corticosteroid Lotion: A 12-Investigator Cooperative Analysis. Current Therapeutic Research, Clinical and Experimental, 14, 638-646.
[38] Jemec, G.B., Ganslandt, C., Ortonne, J.P., Poulin, Y., Burden, A.D., de Unamuno, P., et al. (2008) A New Scalp Formulation of Calcipotriene Plus Betamethasone Compared with Its Active Ingredients and the Vehicle in the Treatment of Scalp Psoriasis: A Randomized, Double-Blind, Controlled Trial. Journal of the American Academy of Dermatology, 59, 455-463.
[39] Green, C., Ganpule, M., Harris, D., Kavanagh, G., Kennedy, C., Mallett, R., et al. (1994) Comparative Effects of Calcipotriol (MC903) Solution and Placebo (Vehicle of MC903) in the Treatment of Psoriasis of the Scalp. British Journal of Dermatology, 130, 483-487.
[40] Pauporte, M., Maibach, H., Lowe, N., Pugliese, M., Friedman, D.J., Mendelsohn, H., et al. (2004) Fluocinolone Acetonide Topical Oil for Scalp Psoriasis. Journal of Dermatological Treatment, 15, 360-364.
[41] Lepaw, M.I. (1978) Double-Blind Comparison of Halcinonide Solution and Placebo Control in Treatment of Psoriasis of the Scalp. Cutis, 21, 571-573.
[42] Ellis, C.N., Horwitz, S.N. and Mente, A. (1988) Amcinonide Lotion 0.1% in the Treatment of Patients with Psoriasis of the Scalp. Current Therapeutic Research, Clinical and Experimental, 44, 315-324.
[43] Shuttleworth, D., Galloway, D.B., Boorman, G.C. and Donald, A.E. (1998) A Double-Blind, Placebo-Controlled Study of the Clinical Efficacy of Ciclopirox Olamine (1.5%) Shampoo for the Control of Scalp Psoriasis. Journal of Dermatological Treatment, 9, 163-167.
[44] Van Voorhees, A.S. and Fried, R. (2009) Depression and Quality of Life in Psoriasis. Postgraduate Medicine, 121, 154-161.
[45] Zampieron, A., Buja, A., Fusco, M., Linder, D., Bortune, M., Piaserico, S., et al. (2015) Quality of Life in Patients with Scalp Psoriasis. Giornale Italiano di Dermatolologia e Venereologia, 150, 309-316.
[46] Mrowietz, U., Macheleidt, O. and Eicke, C. (2011) Effective Treatment and Improvement of Quality of Life in Patients with Scalp Psoriasis by Topical Use of Calcipotriol/Betamethasone (Xamiol®-Gel): Results. Journal der Deutschen Dermatologischen Gesellschaft, 9, 825-831.
[47] Griffiths, C.E., Finlay, A.Y., Fleming, C.J., Barker, J.N., Mizzi, F. and Arsonnaud, S. (2006) A Randomized, Investigator-Masked Clinical Evaluation of the Efficacy and Safety of Clobetasol Propionate 0.05% Shampoo and Tar Blend 1% Shampoo in the Treatment of Moderate to Severe Scalp Psoriasis. Journal of Dermatological Treatment, 17, 90-95.
[48] Wauters, O., Roland, I. and De la Brassinne, M. (2007) Corticosteroids and Their Vehicle in the Treatment of Scalp Psoriasis. Revue Medicale de Liege, 62, 196-199.
[49] Freeman, K. (2010) The Two-Compound Formulation of Calcipotriol and Betamethasone Dipropionate for Treatment of Moderately Severe Body and Scalp Psoriasis—An Introduction. Current Medical Research Opinion, 27, 197-203.
[50] Menter, A., Abramovits, W., Colón, L.E., Johnson, L.A. and Gottschalk, R.W. (2009) Comparing Clobetasol Propionate 0.05% Spray to Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Ointment for the Treatment of Moderate to Severe Plaque Psoriasis. Journal of Drugs in Dermatolology, 8, 52-57.
[51] Meredith, F. and Ormerod, A.D. (2012) Patient Preferences for Psoriasis Treatment: Process Characteristics Considered More Important than Outcome Attributes. Expert Review of Pharmacoeconomics & Outcomes Research, 12, 145-147.
[52] Nast, A., Boehncke, W.H., Mrowietz, U., Ockenfels, H.M., Philipp, S., Reich, K., et al. (2012) Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3—Guidelines on the Treatment of Psoriasis Vulgaris (English Version). Update. Journal der Deutschen Dermatologischen Gesellschaft, 10, S1-S95.
[53] Kortuem, K.R., Davis, M.D., Witman, P.M., McEvoy, M.T. and Farmer, S.A. (2010) Results of Goeckerman Treatment for Psoriasis in Children: A 21-Year Retrospective Review. Pediatric Dermatology, 27, 518-524.
[54] Carretero, G., Puig, L., Dehesa, L., Carrascosa, J.M., Ribera, M., Sánchez-Regana, M., et al. (2010) Metotrexato: Guía de uso en psoriasis (Guidelines on the Use of Methotrexate in Psoriasis). Actas Dermo-Sifiliográficas, 101, 600-613.
[55] Due, E., Blomberg, M., Skov, L. and Zachariae, C. (2011) Discontinuation of Methotrexate in Psoriasis. Acta Dermato Venereologica, 92, 353-354.
[56] Vergou, T., Moustou, A.E., Sfikakis, P.P., Antoniou, C. and Stratigos, A.J. (2011) Pharmacodynamics of TNF-α Inhibitors in Psoriasis. Expert Review of Clinical Pharmacology, 4, 515-523.
[57] Gordon, K., Papp, K., Poulin, Y., Gu, Y., Rozzo, S. and Sasso, E.H. (2012) Long-Term Efficacy and Safety of Adalimumab in Patients with Moderate to Severe Psoriasis Treated Continuously over 3 Years: Results from an Open-Label Extension Study for Patients from REVEAL. Journal of the American Academy of Dermatology, 66, 241-251.
[58] Kimball, A.B., Jacobson, C., Weiss, S., Vreeland, M.G. and Wu, Y. (2005) The Psychosocial Burden of Psoriasis. American Journal of Clinical Dermatology, 6, 383-392.
[59] Kurd, S.K., Troxel, A.B., Crits-Christoph, P. and Gelfand, J.M. (2010) The Risk of Depression, Anxiety, and Suicidally in Patients with Psoriasis: A Population-Based Cohort Study. Archives of Dermatology, 146, 891-895.
[60] Gupta, M.A., Schork, N.J., Gupta, A.K., Kirkby, S. and Ellis, C.N. (1993) Suicidal Ideation in Psoriasis. International Journal of Dermatology, 32, 188-190.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.